Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.42 +1.4%	$1.32	$0.86 ▼ $3.36	$86.01M	0.14	314,599 shs	183,901 shs
ELUT Elutia	$2.02 -6.0%	$2.01	$1.61 ▼ $5.12	$83.06M	0.88	24,996 shs	88,992 shs
EXOZ eXoZymes	$9.70 -2.9%	$10.45	$8.50 ▼ $23.99	$81.38M	N/A	4,225 shs	486 shs
NICXF Nicox	$0.30	$0.27	$0.25 ▼ $0.30	$20.68M	0.33	N/A	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	+4.41%	-5.33%	+32.71%	-44.75%
ELUT Elutia	0.00%	+0.50%	-4.72%	+11.60%	-44.81%
EXOZ eXoZymes	0.00%	-1.42%	+4.86%	-34.90%	+969,999,900.00%
NICXF Nicox	0.00%	0.00%	0.00%	+20.00%	-31.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.0801 of 5 stars	3.5	5.0	0.0	0.0	1.6	1.7	0.6
ELUT Elutia	3.6715 of 5 stars	3.5	5.0	0.0	0.0	2.4	3.3	0.6
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	346.01% Upside
ELUT Elutia	3.00	Buy	$8.00	296.04% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
NICXF Nicox	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NICXF, ELUT, ABOS, and EXOZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$3.03 per share	N/A
ELUT Elutia	$24.38M	3.41	N/A	N/A	($1.31) per share	-1.54
EXOZ eXoZymes	$70K	1,162.61	N/A	N/A	$1.25 per share	7.76
NICXF Nicox	$5.52M	3.75	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	N/A
ELUT Elutia	-$53.95M	-$1.06	N/A	N/A	N/A	-90.01%	N/A	-51.65%	N/A
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A
NICXF Nicox	-$29.25M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/16/2025 (Estimated)

Latest NICXF, ELUT, ABOS, and EXOZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ELUT Elutia	-$0.17	-$0.26	-$0.09	-$0.26	$6.55 million	$6.26 million
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	8.02
ELUT Elutia	N/A	0.81	0.70
EXOZ eXoZymes	0.01	6.19	6.52
NICXF Nicox	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ELUT Elutia	74.03%
EXOZ eXoZymes	N/A
NICXF Nicox	N/A

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	7.10%
ELUT Elutia	27.60%
EXOZ eXoZymes	72.41%
NICXF Nicox	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	56.27 million	Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
NICXF Nicox	28	68.92 million	N/A	Not Optionable

NICXF, ELUT, ABOS, and EXOZ Headlines

Recent News About These Companies

Nicox SA (OTCMKTS:NICXF) Sees Large Increase in Short Interest

August 16 at 3:31 AM | americanbankingnews.com

Nicox Extends Existing Flexible Equity Financing

August 8, 2025 | uk.finance.yahoo.com

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

August 5, 2025 | uk.finance.yahoo.com

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470

July 21, 2025 | ophthalmologytimes.comO

Nicox SA’s Strategic Developments and Promising Trials Justify Buy Rating

July 17, 2025 | tipranks.com

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories

July 17, 2025 | taiwannews.com.twT

Nicox S.A. (NICXF) Stock Price, Quote, News & Analysis

July 1, 2025 | seekingalpha.com

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

June 30, 2025 | ophthalmologytimes.comO

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

June 30, 2025 | manilatimes.netM

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative

June 6, 2025 | santelog.comS

NICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

May 27, 2025 | finanznachrichten.de

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

May 27, 2025 | finance.yahoo.com

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops

May 15, 2025 | ophthalmologytimes.comO

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

May 14, 2025 | finance.yahoo.com

NicOx S.A.

May 10, 2025 | barrons.com

Nicox Provides Full Year 2024 Financial Results

April 30, 2025 | finance.yahoo.com

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

March 24, 2025 | ophthalmologytimes.comO

NICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

March 19, 2025 | finanznachrichten.de

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

March 19, 2025 | markets.businessinsider.com

Nicox presents new analysis from the NCX 470 Mont Blanc trial

March 7, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

NICXF, ELUT, ABOS, and EXOZ Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.42 +0.02 (+1.43%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.42 +0.01 (+0.35%)

As of 08/15/2025 07:52 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Elutia NASDAQ:ELUT

$2.02 -0.13 (-6.05%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.50%)

As of 08/15/2025 04:10 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

eXoZymes NASDAQ:EXOZ

$9.70 -0.29 (-2.90%)

As of 08/15/2025 12:37 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Nicox OTCMKTS:NICXF

$0.30 0.00 (0.00%)

As of 08/15/2025

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time